체외수정 시장, 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global In-Vitro Fertilization Market was valued at USD 20.2 billion in 2023 and is projected to grow at a CAGR of 5.7% from 2024 to 2032, primarily driven by rising infertility rates. As reported by the World Health Organization (WHO), approximately 186 million individuals globally grapple with infertility. Furthermore, conditions like polycystic ovary syndrome (PCOS) and endometriosis, impacting 1 in 10 women worldwide, are fueling the heightened demand for IVF.

In-vitro fertilization is a medical procedure that aids conception by fertilizing an egg in a lab setting outside the human body and subsequently transferring the embryo into the woman's uterus. As a prevalent and effective form of Assisted Reproductive Technology (ART), IVF addresses various infertility challenges, including ovulation disorders, damaged fallopian tubes, and male infertility.

The surging infertility cases significantly propel the market. For instance, WHO data reveals that 1 in 6 individuals globally faces infertility, underscoring the pressing need for fertility care. Technological strides have markedly bolstered IVF success rates. For instance, IVF success rates have surged from roughly 10% in the 1980s to about 30-35% per cycle in 2023, contingent on the woman's age. Time-lapse imaging technology empowers embryologists to closely monitor embryo development, enhancing selection and implantation success rates, and thereby boosting overall IVF success.

The overall industry is classified into product, type of cycle, procedure, end-use, and region.

Market segmentation by product includes equipment, reagents and media, and accessories. The equipment segment, leading the market in 2023 with a valuation of USD 9.4 billion, encompasses a diverse range including microscopes, imaging systems, sperm analyzers, ovum aspiration pumps, micromanipulators, incubators, gas analyzers, cryosystems, laser systems, sperm separation systems, cabinets, anti-vibration tables, witness systems, and other specialized equipment.

Segmentation by cycle type reveals fresh non-donors, frozen non-donors, frozen donors, and fresh donors. The fresh non-donors led with a 48.1% share in 2023, attributed to their superior success rates. Utilizing a woman's own eggs immediately post-retrieval, fresh non-donor cycles boast higher success rates. This advantage stems from the eggs being unaltered by freezing and thawing, processes that could compromise their quality.

North America led the global in-vitro fertilization market with revenue of USD 6.2 billion in 2023, projected to soar to USD 9.8 billion by 2032. Renowned for its cutting-edge medical technology, North American fertility clinics leverage latest advancements in reproductive medicine for ensuring IVF remains both accessible and effective. Factors like delayed childbearing, lifestyle choices, and health conditions contribute to the region's fertility challenges. As many couples postpone parenthood for career or personal reasons, the appetite for fertility treatments, notably IVF, has surged.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing infertility rates
    • 3.2.1.2 Technological advancements and expansion of fertility industry
    • 3.2.1.3 Increasing median age of pregnancy
    • 3.2.1.4 Favorable government initiatives
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs associated with fertility procedures
    • 3.2.2.2 Social and ethical concerns especially in developing countries
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Equipment
  • 5.2.1 Microscope
  • 5.2.2 Imaging system
  • 5.2.3 Sperm analyzer system
  • 5.2.4 Ovum aspiration pump
  • 5.2.5 Micromanipulator system
  • 5.2.6 Incubator
  • 5.2.7 Gas analyzer
  • 5.2.8 Cryosystem
  • 5.2.9 Laser system
  • 5.2.10 Sperm separation system
  • 5.2.11 Cabinet
  • 5.2.12 Anti-vibration table
  • 5.2.13 Witness system
  • 5.2.14 Other equipment
• 5.3 Reagents and media
  • 5.3.1 Embryo culture media
  • 5.3.2 Cryopreservation media
  • 5.3.3 Sperm processing media
  • 5.3.4 Ovum processing media
• 5.4 Accessories

Chapter 6 Market Estimates and Forecast, By Type of Cycle, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Fresh non-donors
• 6.3 Frozen non-donors
• 6.4 Frozen donors
• 6.5 Fresh donors

Chapter 7 Market Estimates and Forecast, By Procedure, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Conventional IVF
• 7.3 IVF with intracytoplasmic sperm injections
• 7.4 Minimal IVF
• 7.5 IVF with donor eggs
• 7.6 Other procedures

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Fertility clinics and IVF centers
• 8.3 Hospitals and surgical centers
• 8.4 Research institutes
• 8.5 Cryobanks

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Cook Medical
• 10.2 Esco Medical
• 10.3 FUJIFILM Irvine Scientific, Inc.
• 10.4 GE HealthCare Technologies, Inc.
• 10.5 Genea BIOMEDX
• 10.6 Gynemed GmbH and Co. KG
• 10.7 Hamilton Thorne Ltd.
• 10.8 IVFtech ApS
• 10.9 Kitazato Corporation
• 10.10 Merck KGaA
• 10.11 Nidacon International AB
• 10.12 The Baker Company Inc.
• 10.13 The Cooper Companies Inc.
• 10.14 Thermo Fisher Scientific Inc.
• 10.15 Vitrolife Group